Bazedoxifene

Bazedoxifene
Systematic (IUPAC) name
1-[4-(2-azepan-1-ylethoxy)benzyl]-2- (4-hydroxyphenyl)-3-methyl-1H-indol-5-ol
Identifiers
CAS number	198481-32-2
ATC code	?
PubChem	154257
Chemical data
Formula	C30H34N2O3
Mol. mass	470.603 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

WikiDoc Resources for Bazedoxifene
Articles
Most recent articles on Bazedoxifene Most cited articles on Bazedoxifene Review articles on Bazedoxifene Articles on Bazedoxifene in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bazedoxifene Images of Bazedoxifene Photos of Bazedoxifene Podcasts & MP3s on Bazedoxifene Videos on Bazedoxifene
Evidence Based Medicine
Cochrane Collaboration on Bazedoxifene Bandolier on Bazedoxifene TRIP on Bazedoxifene
Clinical Trials
Ongoing Trials on Bazedoxifene at Clinical Trials.gov Trial results on Bazedoxifene Clinical Trials on Bazedoxifene at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bazedoxifene NICE Guidance on Bazedoxifene NHS PRODIGY Guidance FDA on Bazedoxifene CDC on Bazedoxifene
Books
Books on Bazedoxifene
News
Bazedoxifene in the news Be alerted to news on Bazedoxifene News trends on Bazedoxifene
Commentary
Blogs on Bazedoxifene
Definitions
Definitions of Bazedoxifene
Patient Resources / Community
Patient resources on Bazedoxifene Discussion groups on Bazedoxifene Patient Handouts on Bazedoxifene Directions to Hospitals Treating Bazedoxifene Risk calculators and risk factors for Bazedoxifene
Healthcare Provider Resources
Symptoms of Bazedoxifene Causes & Risk Factors for Bazedoxifene Diagnostic studies for Bazedoxifene Treatment of Bazedoxifene
Continuing Medical Education (CME)
CME Programs on Bazedoxifene
International
Bazedoxifene en Espanol Bazedoxifene en Francais
Business
Bazedoxifene in the Marketplace Patents on Bazedoxifene
Experimental / Informatics
List of terms related to Bazedoxifene

Bazedoxifene is a selective estrogen receptor modulator (SERM), developed by Wyeth Pharmaceuticals, undergoing clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. It is currently in the early phases of review by the United States' Food and Drug Administration. When approved, bazedoxifene is to be sold by Wyeth under the tradename Viviant™. Bazedoxifene's combination with conjugated estrogens, Aprela™, is currently undergoing Phase III studies.

Wyeth received an approvable letter for Bazedoxifene in late April 2007. The FDA called for final safety and efficacy data from Phase III studies, and acceptable valuation of manufacturing and testing facilities where problems were found earlier in the year. Wyeth is working with the FDA to resolve these issues, and expects an FDA action date at year end.

CITATIONS

BROWN, EMILY. Wyeth's osteoporosis drug cut risk of new fractures. Retrieved on 2007-09-28. Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis. Retrieved on 2007-09-28.